Celiac Disease Pipeline Analysis: Emerging Therapies, Market Trends, and Next-Generation Treatment Innovations Transforming the Celiac Disease Drug Market | DelveInsight

DelveInsight's Celiac Disease Pipeline Insight 2026 report provides comprehensive global coverage of marketed and pipeline therapies for Celiac Disease across various stages of clinical development. The report delivers in-depth insights into the evolving Celiac Disease treatment landscape, emerging therapies, pipeline innovations, market trends, competitive intelligence, and future growth opportunities shaping the Celiac Disease market, treatment market, and autoimmune disease industry.

Key Takeaways from the Celiac Disease Pipeline and Treatment Landscape Report

• DelveInsight's Celiac Disease pipeline analysis highlights a robust therapeutic landscape with multiple companies advancing innovative immunotherapies, peptide-based therapies, monoclonal antibodies, and disease-modifying treatments.
• Key Celiac Disease companies such as Takeda, Forte Biosciences, Immunic Therapeutics, Barinthus Biotherapeutics, Allero Therapeutics, and Parvus Therapeutics are actively contributing to pipeline growth.
• Promising Celiac Disease pipeline therapies include TAK-101, FB102, IMU-856, VTP-1000, ALL-001, and PVT-301.
• Increasing understanding of disease pathogenesis and immune mechanisms is accelerating the development of targeted therapies for Celiac Disease.
• Advancements in immune tolerance therapies, immunomodulators, and antigen-specific treatments continue to create significant opportunities across the Celiac Disease treatment market and drug industry.
Request a sample and discover the latest advancements in Celiac Disease treatment drugs, emerging therapies, market size, market share, and pipeline developments. Celiac Disease Pipeline

What is Celiac Disease?

Celiac Disease, also known as gluten-sensitive enteropathy, is a chronic autoimmune disorder in which ingestion of gluten triggers an abnormal immune response, resulting in inflammation and damage to the small intestine. The disease affects nutrient absorption and can cause a wide range of gastrointestinal and systemic manifestations.
Common symptoms include chronic diarrhea, abdominal pain, bloating, constipation, nausea, fatigue, anemia, joint pain, headaches, and neurological complications. In children, Celiac Disease may also result in delayed growth and behavioral changes. The disease affects approximately 0.5% to 1% of the global population and is more common among individuals with autoimmune disorders such as Type 1 Diabetes. First-degree relatives of affected patients face a significantly increased risk of developing the condition.
Although a strict gluten-free diet remains the standard of care, the growing burden of disease and challenges associated with long-term dietary adherence are driving innovation within the Celiac Disease drug market and treatment landscape.
Emerging Celiac Disease Drug Profiles

TAK-101: Takeda
TAK-101 is an investigational immune tolerization therapy designed to restore immune tolerance to gluten in patients with Celiac Disease. The therapy consists of gluten proteins encapsulated within polymer-based nanoparticles and is administered intravenously. Once delivered to the spleen and liver, TAK-101 promotes immune tolerance mechanisms that prevent harmful immune responses against gluten.
The therapy has demonstrated significant reductions in gluten-induced immune activation and is currently being evaluated in Phase II clinical development for Celiac Disease.

FB102: Forte Biosciences
FB102 is a monoclonal antibody therapy currently being developed in Phase II clinical studies. The therapy has emerged as one of the most promising candidates in the Celiac Disease pipeline and recently received Fast Track Designation from the FDA, highlighting its potential to address significant unmet needs in the treatment landscape.

IMU-856: Immunic Therapeutics
IMU-856 is an orally administered small-molecule therapy currently progressing through Phase I development. The candidate is designed to support intestinal barrier function and represents a novel therapeutic approach within the Celiac Disease treatment market.

VTP-1000: Barinthus Biotherapeutics
VTP-1000 is a gluten-derived peptide immunotherapy currently being evaluated in Phase I clinical development. The therapy is designed to enhance regulatory immune responses while suppressing pathogenic effector T-cell activity associated with gluten exposure.
Learn more about the novel and emerging Celiac Disease pipeline therapies driving innovation across the Celiac Disease treatment market and autoimmune disease industry. Celiac Disease Pipeline

Recent Developments in the Celiac Disease Clinical Trial Landscape

• In May 2026, Forte Biosciences announced that FB102 received FDA Fast Track Designation for Celiac Disease, underscoring the significant unmet need and potential clinical value of the therapy.
• In December 2025, Barinthus Biotherapeutics provided an update from its first-in-human Phase I trial of VTP-1000, with additional clinical data expected during the second half of 2026.
• In September 2025, Forte Biosciences presented additional clinical findings supporting FB102's ability to prevent histological damage and mitigate gluten challenge-induced symptoms in patients with Celiac Disease.
• In January 2026, Royalty Pharma and Teva Pharmaceuticals announced a funding agreement of up to USD 500 million to accelerate development of anti-IL-15 antibody TEV-408 for immune-mediated diseases, including potential autoimmune indications.
• TAK-101 completed its Phase II clinical trial in January 2026 following enrollment of 102 participants, further advancing the immune tolerance treatment approach in Celiac Disease.
Scope of the Celiac Disease Pipeline Report
• Coverage: Global
• Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy, Mono/Combination
• Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase I/II, Phase II, Phase III
• Therapeutic Assessment by Route of Administration: Oral, Intravenous, Intramuscular, Subcutaneous, and Others
• Therapeutic Assessment by Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Cell Therapies, Nanoparticle-Based Therapies, and Other Emerging Modalities
• Key Celiac Disease Companies: Takeda, Forte Biosciences, Immunic Therapeutics, Barinthus Biotherapeutics, Allero Therapeutics, Parvus Therapeutics, and others.
• Key Celiac Disease Pipeline Therapies: TAK-101, FB102, IMU-856, VTP-1000, ALL-001, PVT-301, and others.
Dive deep into rich insights for new Celiac Disease treatment drugs, clinical trial developments, market size, market share, competitive intelligence, and future forecasts. Celiac Disease Pipeline

Table of Contents

• Celiac Disease Pipeline Report Introduction
• Executive Summary
• Celiac Disease Overview
• Signs and Symptoms
• Pathogenesis
• Diagnosis
• Treatment Landscape
• Pipeline Therapeutics
• Late-Stage Products
• Mid-Stage Products (Phase II)
• Early-Stage Products (Phase I/II)
• Early-Stage Products (Phase I)
• Preclinical Products
• Discovery-Stage Products
• Therapeutic Assessment
• Product Type Assessment
• Route of Administration Assessment
• Molecule Type Assessment
• Inactive Products Analysis
• Collaborations Assessment
• Unmet Needs
• Market Drivers and Barriers
• References
• Report Methodology
• About DelveInsight

For further information on the Celiac Disease pipeline therapeutics, emerging treatment landscape, market trends, market share analysis, and future commercial opportunities, reach out today. Celiac Disease Pipeline

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.